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WILLIAMSON, B.D., ET AL.: The Economic Impact of Transvenous Defibrillation Lead Systems. The
purpose of this study was to compare implant charges and convalescence for transvenous and epicardial
defibrillation systems. Hospital stay, intensive care utilization, professional fees, and hospital bills were
compared in 44 patients who underwent implantation of a cardiac defibrillator between September 1991
and May 1993. Twenty-five consecutive patients received an epicardial lead system, while 19 consecutive
patients underwent implantation of the entire transvenous defibrillation system in the electrophysiology
laboratory. There were no significant differences between the two groups in mean age or left ventricular
ejection fraction. There was a significant reduction in postoperative hospital convalescence from 7.2 ±
2.0 days witb epicardial systems to 3.1 ± 1.5 days with transvenous systems (P < 0.001). Postoperative
intensive care unit stay was significantly reduced with transvenous systems compared with epicardial
systems (0.1 ± 0.2 vs 1.5 ± 0.9 days;P <0.001). Hospital charges were also significantly reduced with the
transvenous lead system implants. Mean implant charges were lower with transvenous systems: $32,090 ±
$2,620 vs $38,307 ± $2,701 (P < 0.001); convalescence charges were lower: $5,861 ± $5,010 vs $12,447
± $4,969 (P < 0.001); the total hospital bill was also significantly lower with transvenous systems: $53,459
± $12,588 vs $71,981 ± $16,172 (P < 0.001). Professional fees for implantation ($4,131 ± $1,724 vs
$6,100 ± 0, P < 0.001), convalescence care ($1,258 ± $960 vs $2,846 ± $1,770; P < 0.001), and total
professional fees ($12,925 ± $4,772 vs $15,731 ± $4,055, P < 0.05) were lower in the transvenous defibril-
lation group. In conclusion, transvenous defibrillation lead systems are associated with significantly
shorter postoperative recovery and significantly lower hospital and professional charges. (PACE 1994;
17[Pt. 11:2297-2303)
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Introduction
Cardiac defibrillators using epicardial defi-
hrillation lead systems vî ere approved for clinical
use hy the Food and Drug Administration on Octo-
her 4, 1985.^ Since that time, several studies have
suggested that the implantahle defihrillator pro-
longs survival in patients who are at risk of ar-
rhythmic death. ̂ "̂  With this sophisticated tech-
nology comes a suhstantial financial cost. Not only
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is the device expensive, hut implantation of this
defibrillation system requires entry into the
thorax. The convalescence in these patients in-
volves a stay in the intensive care unit, followed
hy several additional days in the hospital prior to
discharge. Nevertheless, cost analysis studies have
suggested that implantable defihrillators with epi-
cardial defihrillation systems have a cost that com-
pares favorahly with that of other life-saving inter-
ventions.^'''
A transvenous defibrillation lead system was
approved for clinical use by the Food and Drug
Administration in August 1993.** Transvenous de-
fihrillation lead systems eliminate the need for
entry into the thorax, which may result in lower
morhidity and mortality and a shorter hospitaliza-
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tion. The purpose of this study was to compare
the total charges and duration of convalescence in
patients undergoing implantation of transvenous
and epicardial defibrillation lead systems.
Methods
Subjects of Study
All patients with aborted sudden cardiac
death not due to correctable causes or with medi-
cally refractory ventricular tachycardia receiving
a clinically available cardiac defibrillator at the
University of Michigan between September 1991
and May 1993 were considered for evaluation. Pa-
tients requiring concomitant cardiac surgery were
excluded. All patients underwent a baseline elec-
trophysiological study in the absence of antiar-
rhythmic agents. If monomorphic ventricular
tachycardia was induced with programmed stimu-
lation during the baseline study, electropharmaco-
logical testing was performed. Patients who con-
tinued to have inducihle ventricular tachycardia
despite drug therapy or v̂ rho did not have induci-
hle ventricular tachycardia during the baseline
study underwent cardiac defihrillator implanta-
tion. The epicardial group consisted of 25 patients
who received an epicardial lead system hefore an
investigational defibrillation lead system was
availahle in our institution. Once investigational
transvenous defibrillation lead systems became
available, all patients undergoing cardiac defihril-
lator implantation without concomitant cardiac
surgery were eligible for the transvenous defibril-
lation lead system. The transvenous defihrillation
group consisted of 19 consecutive patients receiv-
ing an investigational transvenous defihrillation
lead system made hy Cardiac Pacemakers, Incor-
porated (CPI, St. Paul, MN, USA). All patients in
this analysis received clinically availahle defihril-
lator generators. Patients who underwent implan-
tation of a transvenous lead system provided in-
formed consent under an investigational protocol
approved by the Human Research Committee.
The total study group consisted of 44 patients
receiving implantahle cardiac defihrillators (Tahle
I). Among the 25 patients who received a cardiac
defihrillator with an epicardial defihrillation sys-
tem, 16 were noninducihle during the initial elec-
trophysiological study. The remaining nine pa-
Table 1.
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There were no significant differences between the two groups.
tients failed a mean of 1.8 drug trials prior to im-
plantation. Among the 19 patients who received a
cardiac defihrillator with a transvenous lead sys-
tem, 10 patients were noninducihle during the
haseline electrophysiological study. The other
nine patients failed a mean of two drug trials prior
to implantation. There were no significant differ-
ences hetween the two groups in age, ejection frac-
tion. New York Heart Association class, or prior
antiarrhythmic therapy.
Implantation of Epicardial Lead Systems
In the epicardial group, the surgical approach
for implantation of epicardial lead systems was
median sternotomy or left anterior thoracotomy.
Implantation was performed in the operating room
with the patient under general anesthesia. Two
large patch leads were used in the majority of pa-
tients, and two epicardial rate sensing leads were
placed in all epicardial systems. Intraoperative de-
fihrillation was performed to confirm consistent
defihrillation with 20 joules or less. Postopera-
tively, all patients undergoing thoracotomy were
monitored for at least 24 hours in an intensive care
unit. Patients were moved to a monitored interme-
diate care unit once they were stahle.
Implantation of Transvenous Lead Systems
In the transvenous group, the entire implanta-
tion procedure was performed in the electrophysi-
ology lahoratory with the patient under general an-
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esthesia. Venous access for the transvenous defi-
brillation lead in most patients was through the
left subclavian vein, unless existing pacemaker
hardware or other surgical factors required entry
by the right subclavian vein. The defibrillator lead
was positioned in the right ventricular apex to
achieve satisfactory bipolar sensing and pacing.
Conversion of ventricular fibrillation was first
tested using a lead alone. Nine patients with defi-
brillation thresholds higher than 25 joules with
transvenous lead alone underwent implantation of
a subcutaneous subaxillary patch electrode.
All patients went to a postoperative observa-
tion area after the completion of the transvenous
implant procedure. They remained there until the
anesthesiologist judged them stable to return to
their room in an intermediate care monitored unit.
One of 19 patients receiving a transvenous defibril-
lation system was monitored overnight in an inten-
sive care unit. All patients underwent a predis-
charge test of the cardiac defibrillator.
Postoperative Recovery
All patients had satisfactory defibrillation at
initial implant. One patient in the epicardial lead
system group had unsatisfactory defibrillation at
the predischarge test, and underwent additional
implantation of a spring lead in the superior vena
cava-right atrium to achieve satisfactory defibrilla-
tion. One patient in each group underwent im-
plantation of a dual chamber pacemaker prior to
discbarge from the hospital. One patient in the epi-
cardial group developed postoperative atrial fibril-
lation with a rapid ventricular response, resulting
in several defibrillator discharges; another patient
in tbis group developed a sterile fluid collection
around the defibrillator generator. One patient in
the transvenous group had inadvertent entry into
the abdominal cavity tbrough a preexisting ventral
hernia when the generator pocket was formed,
without clinical sequelae. Another patient in the
transvenous group had mild postoperative corneal
abrasions of one eye, which resolved with conserv-
ative therapy. There were no deaths or serious
complications from defibrillator implantation in
either group.
Analysis of Charges and Convalescence
All hospital charges during the hospitaliza-
tion in which the defibrillator implant occurred
were analyzed. Itemized bills were obtained ftom
the patient accounts office. The hospital charges
included charges for room and board, electrophys-
iology, and operating room charges, nursing aiid
ancillary care, blood tests, chest roentgenograms,
electrocardiograms, cardiac imaging studies, and
pharmacy charges. Implant-related charges were
defined as all hospital charges generated on the
day of implantation, including direct operating
room and supply charges, device charges, radiol-
ogy and laboratory fees, patient room and recovery
room charges where applicable. Convalescence
charges included all charges incurred from tbe day
after implantation until discbarge, including pa-
tient room, pharmacy, laboratory, and radiology
charges. All patients underwent a predischarge
test of the cardiac defibrillator in the electrophysi-
ology laboratory, the fee for which was included
in convalescence charges.
Physician charges were obtained from the rel-
evant physician associates group at tbe University
of Michigan (i.e., Internal Medicine, Thoracic Sur-
gery, and Anesthesiology). To account for any
changes in charges due to inflation, cost data in
this study were adjusted to 1993 dollars. Hospital
and physician charges were adjusted using an av-
erage annual inflation rate obtained from the Uni-
versity of Michigan Medical Center budget and
medical service plan offices, respectively.
Return to Work
Follow-up telephone interviews were con-
ducted to assess postimplantation employment
status. Interviews included demographics, such as
marital status, number of children, and years of
formal education. Full- or part-time employment
status as well as occupational level (unskilled,
skilled, technical, and professional) were also as-
sessed. Finally the level of reemployment and
days until return to work were obtained.
Statistical Analysis
Data are reported as mean ± standard devia-
tion. Continuous variables were compared witb
Student's t- test. Discrete variables were compared
by contingency table analysis. A P value < 0.05
was considered statistically significant.




Patients receiving an implantable cardiac de-
fibrillator witb an epicardial defibrillation lead
system incurred an average of $87,318 ± $14,046
in total cbarges, including botb total bospital
cbarges and professional fees. In contrast, patients
wbo received an implantable cardiac defibrillator
utilizing a transvenous defibrillation lead system
bad a significantly lower mean total cbarge of
$66,627 ± $18,867 (P < 0.001).
Professional Fees
Tbe professional fees were similar in tbe two
groups for tbe preimplantation period of tbe bospi-
talization (Table II), witb mean professional fees
in tbe epicardial group of $6,192 ± $3,631, and
$6,390 ± $4,266 in the transvenous group (P =
NS). Tbese fees represent tbe total professional
fees during tbe evaluation phase prior to implanta-
tion, including electropbysiological studies, car-
diac catbeterizations, electrocardiograms, ecbo-
cardiogram and nuclear study interpretation, as
well as patient care days.
Tbe implantation professional fees were tbose
fees incurred on tbe day of defibrillator implanta-
tion. Epicardial lead system implantations re-
sulted in professional fees of $6,100 ± 0, wbereas
transvenous lead system implants resulted in
professional fees of $4,131 ± $1,724, wbicb were
significantly lower (P < 0.001). Tbe difference in
tbe observed fees was due to tbe involvement of
only one pbysician group (electropbysiologist)
performing tbe transvenous lead system implanta-
tion compared to a cardiothoracic surgeon and
electrophysiologist in the epicardial lead system
implantations.
Tbe professional fees during tbe convales-
cence period were significantly lower for patients
witb transvenous lead systems. The fees incurred
for convalescence care included not only a predis-
charge test of the cardiac defibrillator, but also in-
terpretations of electrocardiograms, arterial blood
gases, ecbocardiograms (if performed), and any
medical consultations. Patients receiving an epi-
cardial lead system incurred $2,846 ± $1,770 of
professional cbarges during tbe convalescence pe-
riod, compared witb $1,258 ± $960 for patients
witb transvenous lead systems, a difference tbat
was statistically significant (P < 0.001). Tbis over-
all reduction in professional service utilization
was also reflected in significantly lower total
professional fees in tbe transvenous lead system
group ($12,925 ± $4,772 vs $15,731 ± $4,055 in
the epicardial group, P < 0.05).
Hospital Charges
There were significantly lower bospital
cbarges for patients receiving a transvenous car-
diac defibrillation system compared witb patients
receiving epicardial lead systems (Table III). Im-
plant-related cbarges, reflecting all bospital
cbarges incurred on the day of implantation, were
lower in the transvenous group: $38,307 ± $2,701
versus $32,090 ± $2,620 in the epicardial group
(P < 0.001). There was also a significant reduction
in hospital charges incurred during the subsequent
bospital convalescence. Tbe epicardial group in-
curred $12,447 ± $4,969 in cbarges during tbe
mean of 7.2 days of convalescence; tbe transve-




























Comparison of total professional fees for epicardial and transvenous defibrillation lead systems, respectively.
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during 3.1 days of convalescence, a 55% reduction
in convalescence charges, which was statistically
significant (P < 0.001).
Length of Hospitalization and Convalescence
Patients in the epicardial group had an aver-
age total length of stay of 18.7 ± 6.1 days, with
7.2 ± 2.0 days spent as in-hospital convalescence
after defihrillator implantation (Tahle III). The av-
erage intensive care unit convalescence in the epi-
cardial group was 1.5 ± 0.9 days. One patient re-
mained in the intensive care unit for 3 days, and
another for 5 days after surgery. In comparison,
patients receiving a transvenous cardiac defihrilla-
tion lead system had a significantly shorter hospi-
tal stay, 14.2 ± 6.2 days (P < 0.01). This difference
was due to a shorter total postimplant convales-
cence time of 3.1 ± 1.5 hospital days (P < 0.001).
The patients in the transvenous group also re-
quired significantly less intensive care convales-
cence following implant, 0.1 ± 0.2 days, with only
one patient spending 1 day in the intensive care
unit (P < 0.001).
Return to Work
Five patients in the epicardial group were em-
ployed prior to implantation of the defihrillator,
and three have returned to work during the follow-
up period (Tahle IV). The mean time for returning
to work was 104 days, (range 42-180 days). Seven
patients in the transvenous group were employed
prior to implantation, and three returned to work
afterwards, with a mean time to return of 66 days
(range 7-150 days). No patient in either group who




The care of patients with ahorted sudden
death or ventricular tachycardia is expensive he-
cause of the required diagnostic evaluation, hospi-
talization, and therapy. If the decision is made to
implant a cardiac defibrillator, considerable ex-
pense is incurred from the operative implant, the
cost of the device, and the suhsequent postimplant
convalescence. The results of this study demon-
strate an overall savings of 23% in hospital charges
and professional fees in patients receiving an im-
plantahle cardiac defihrillator utilizing a transve-
nous lead system compared to an epicardial defi-
hrillation system. Transvenous defihrillation lead
systems offer a significant reduction in consump-
tion of expensive hospital resources compared























* Average days until return to previous level of employment. Differ-
ence not statistically significant.
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Professional Fees
The professional component of patient
charges was 17% lower in patients receiving a
transvenous lead system compared with epicar-
dial systems. There was no difference in profes-
sional fees for the preimplantation period of the
hospitalization. This confirms the similarity in pa-
tient complexity in the two groups prior to implan-
tation. Implantation professional fees were signifi-
cantly lower, resulting in a 32% savings for the
professional component of implant charges. This
reduction in incurred charges resulted from the
ability of the transvenous system to be implanted
by an electrophysiologist without the involvement
of a cardiothoracic surgeon. Professional charges
in the transvenous group were 63% lower during
the convalescence period, reflecting the shorter
postoperative hospitalization and lower complex-
ity of postoperative care in these patients.
Hospital Charges
This study examined the impact of transve-
nous defibrillation lead systems on hospital
charges as a measure of their impact on cost effec-
tiveness. Hospital charges are not the same as
"cost," nor do hospital charges reflect reimburse-
ment from third-party payers. However, it is gener-
ally acknowledged that hospital charges are pro-
portional to the consumption of resources. Reduc-
tions in accrued charges for similar services
should reflect a legitimate reduction in resource
consumption. In this study, not only were charges
reduced, but the transvenous defibrillation lead
system also resulted in a significant reduction in
length of stay and intensity of care.
Return to Work
As a previous study of return to employment
in patients receiving epicardial defibrillation sys-
tems found, the employment status prior to defi-
brillator implantation has a strong influence on
subsequent employment.^ The number of patients
in this study who were employed prior to implan-
tation of their cardiac defibrillator was low. No
patients who were on medical disability or who
were retired prior to implantation became em-
ployed after implant. Although the number of pa-
tients who returned to work in each group was
small, there was a trend toward earlier return to
work in patients who received a transvenous defi-
brillation system.
Comparison with Other Studies
The patients receiving epicardial defibrilla-
tion systems in this study had hospital costs and
length of stay similar to a recently published anal-
ysis of the cost effectiveness of automatic defibril-
lator implantation.'' In that study, patients who
failed drug therapy underwent left anterior thora-
cotomy or subxiphoid implantation of the defibril-
lation system, with a subsequent average hospital
stay of 26.3 days and an average cost of $73,400,
Furthermore, early implantation of a cardioverter-
defibrillator without drug testing resulted in an av-
erage length of stay of 12.6 days and an average
cost of $40,400, both of which were significantly
lower than in patients who first underwent drug
testing. Given the findings in the current study,
early implantation of a transvenous cardiac defi-
brillator may be the most cost-efficient way to treat
patients who have had a life-threatening arrhyth-
mia. Future efficacy studies comparing early im-
plantation of a transvenous defibrillator system
with long-term drug therapy will be necessary to
further investigate this possibility.
No previous study has addressed the impact
of transvenous defibrillator systems on out-of-hos-
pital convalescence or returning to work. A shorter
time for return to previous activities after transve-
nous defibrillator implantation could offer a sig-
nificant financial benefit to those patients who do
return to work. Although many patients may not
be employed due to advanced age, poor cardiac
function, or other medical problems, shorter post-
discharge convalescence also allows for improved
quality of life.
Limitations
This study focused on differences in the im-
mediate postoperative convalescence and on the
impact of defibrillation lead systems on the cost
of the initial hospitalization, but did not examine
tbe cost of care during long-term follow-up. During
tbe initial investigational pbase, a 2-month elec-
trophysiological study to reevaluate efficacy of de-
fibrillation was required in the transvenous group,
but not in tbe epicardial system group. However,
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because the Endotak lead system has been clini-
cally released by the Food and Drug Administra-
tion, the need for a 2-month follow-up study is
now at the discretion of the following physician.
In the manufacturer-reported experience in 1,432
patients with the Endotak lead, 1.4% of patients
were found to have nonconversion of arrhythmia
8—12 weeks postimplant, and 0.3% were found to
have nondetection of arrhythmia.^ As with the epi-
cardial lead systems, follow-up testing should be
performed when clinically indicated. Since the de-
fibrillator generator is the same for both defibrilla-
tion lead systems, the clinical follow-up is other-
wise the same.
Although all patients in this study had suc-
cessful defibrillation with the transvenous lead
system, some patients may not achieve satisfactory
defibrillation without epicardial patches. In the
initially reported manufacturer experience, 1,432
of 1,652 (86%) of patients underwent successful
implantation of a transvenous system. In the latter
part of the study, the implant success rate was
91.2% (611 of 670 patients). In the limited number
of patients who require epicardial patches after at-
tempted transvenous implantation, the cost of care
increases. Future advances in defibrillation tech-
nology, including biphasic waveforms, may fur-
ther improve the efficacy of transvenous defibrilla-
tion. Additionally, technological advances in defi-
brillation efficacy and reduction in generator size
may allow for prepectoral implantation, which
might eliminate the need for general anesthesia
and its associated cost.
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